The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Abstract
Background Four new oral anticoagulants compare favourably with warfarin for stroke prevention in patients with atrial fibrillation; however, the balance between efficacy and safety in subgroups needs better definition. We aimed to assess the relative benefit of new oral anticoagulants in key subgroups, and the effects on important secondary outcomes.Methods We searched Medline from Jan 1, 2009, to Nov 19, 2013, limiting searches to phase 3, randomised trials of patients with atrial fibrillation who were randomised to receive new oral anticoagulants or warfarin, and trials in which both efficacy and safety outcomes were reported. We did a prespecified meta-analysis of all 71,683 participants included in the RE-LY, ROCKET AF, ARISTOTLE, and ENGAGE AF-TIMI 48 trials. The main outcomes were stroke and systemic embolic events, ischaemic stroke, haemorrhagic stroke, all-cause mortality, myocardial infarction, major bleeding, intracranial haemorrhage, and gastrointestinal bleeding. We calculated relative risks (RRs) and 95% CIs for each outcome. We did subgroup analyses to assess whether differences in patient and trial characteristics affected outcomes. We used a random-effects model to compare pooled outcomes and tested for heterogeneity.Findings 42,411 participants received a new oral anticoagulant and 29,272 participants received warfarin. New oral anticoagulants significantly reduced stroke or systemic embolic events by 19% compared with warfarin (RR 0·81, 95% CI 0·73-0·91; p<0·0001), mainly driven by a reduction in haemorrhagic stroke (0·49, 0·38-0·64; p<0·0001). New oral anticoagulants also significantly reduced all-cause mortality (0·90, 0·85-0·95; p=0·0003) and intracranial haemorrhage (0·48, 0·39-0·59; p<0·0001), but increased gastrointestinal bleeding (1·25, 1·01-1·55; p=0·04). We noted no heterogeneity for stroke or systemic embolic events in important subgroups, but there was a greater relative reduction in major bleeding with new oral anticoagulants when the centre-based time in therapeutic range was less than 66% than when it was 66% or more (0·69, 0·59-0·81 vs 0·93, 0·76-1·13; p for interaction 0·022). Low-dose new oral anticoagulant regimens showed similar overall reductions in stroke or systemic embolic events to warfarin (1·03, 0·84-1·27; p=0·74), and a more favourable bleeding profile (0·65, 0·43-1·00; p=0·05), but significantly more ischaemic strokes (1·28, 1·02-1·60; p=0·045).Interpretation This meta-analysis is the first to include data for all four new oral anticoagulants studied in the pivotal phase 3 clinical trials for stroke prevention or systemic embolic events in patients with atrial fibrillation. New oral anticoagulants had a favourable risk-benefit profile, with significant reductions in stroke, intracranial haemorrhage, and mortality, and with similar major bleeding as for warfarin, but increased gastrointestinal bleeding. The relative efficacy and safety of new oral anticoagulants was consistent across a wide range of patients. Our findings offer clinicians a more comprehensive picture of the new oral anticoagulants as a therapeutic option to reduce the risk of stroke in this patient population.Funding None.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Oral anticoagulation (OAC) with vitamin K antagonists (VKAs) or non-VKA oral anticoagulants (NOACs) markedly reduces stroke and mortality in AF patients.38,39”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“OAC therapy can prevent the majority of ischaemic strokes in AF patients and can prolong life.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“and hence there is strong evidence that patients with a CHA 2 DS 2 -VASc risk score of 2 or more in men, and 3 or more in women benefit from OAC.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“Controlled trials studying OAC in AF patients have been enriched for patients at high risk of stroke, 38,39,42,194,201,329,351,352”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“Mortality was 10% lower in patients randomized to NOAC therapy (RR 0.90; 95% CI 0.85-0.95;P = 0.0003) and intracranial haemorrhage was halved (RR 0.48; 95% CI 0.39-0.59;P < 0.0001), while gastrointestinal bleeding events were more frequent (RR 1.25; 95% CI 1.01-1.55;P = 0.04).39”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“NOACs in these dosages significantly reduced stroke or systemic embolic events by 19% compared with warfarin (RR 0.81; 95% CI 0.73-0.91;P < 0.0001), mainly driven by a reduction in haemorrhagic stroke (RR 0.49; 95% CI 0.38-0.64;P < 0.0001).”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“A meta-analysis 39 based on the highdose treatment groups of the pivotal studies of warfarin versus NOACs included 42,411 patients receiving a NOAC and 29,272 receiving warfarin.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“Good data are available to support the use of anticoagulants in older patients from BAFTA (Birmingham Atrial Fibrillation Treatment of the Aged Study), 362 the NOAC trials, 39 and from analyses in elderly Americans (Medicare).396”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Kirchhof, P. F., Lip, G. Y. H., Schotten, U., Savelieva, I., Ernst, S., Gelder, I. C. V., Al‐Attar, N., Hindricks, G., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq278 · Cited by 5,924
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
Pisters, R., Lane, D. A., Nieuwlaat, R., de Vos, C. B., Crijns, H. J. G. M., & Lip, G. Y. H. (2010) · CHEST Journal · doi:10.1378/chest.10-0134 · Cited by 4,517
Cited by
Sorted by citations
Items 301–400 of 1,004
Ageno, W., Vedovati, M. C., Cohen, A. T., Huisman, M. V., Bauersachs, R. M., Gussoni, G., Becattini, C., & Agnelli, G. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1720975 · Cited by 108
Ischemic Stroke Risk in Patients With Atrial Fibrillation and CHA 2 DS 2 -VASc Score of 1
Joundi, R. A., Cipriano, L. E., Sposato, L. A., & Saposnik, G. (2016) · Stroke · doi:10.1161/strokeaha.115.012609 · Cited by 106
Ruff, C. T., Giugliano, R. P., & Antman, E. M. (2016) · Circulation · doi:10.1161/circulationaha.116.021831 · Cited by 109
Anticoagulant-Associated Intracranial Hemorrhage in the Era of Reversal Agents
Steiner, T., Weitz, J. I., & Veltkamp, R. C. (2017) · Stroke · doi:10.1161/strokeaha.116.013343 · Cited by 105
Atrial high-rate episodes and stroke prevention
Camm, A. J., SIMANTIRAKIS, E. N., Goette, A., Lip, G. Y. H., Vardas, P. E., Calvert, M., CHLOUVERAKIS, G. I., Diener, H., & Kirchhof, P. F. (2016) · EP Europace · doi:10.1093/europace/euw279 · Cited by 104
Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation
Korompoki, E., Filippidis, F. T., Nielsen, P. B., Giudice, A. D., Lip, G. Y. H., Kuramatsu, J. B., Huttner, H. B., Fang, J., Schulman, S., Martí‐Fábregas, J., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004235 · Cited by 102
Lee, S., Choi, E., Kwon, S., Han, K., Jung, J., Cha, M., Oh, S., & Lip, G. Y. H. (2019) · Stroke · doi:10.1161/strokeaha.119.025536 · Cited by 103
Nielsen, P. B., Larsen, T. B., Skjøth, F., Overvad, T. F., & Lip, G. Y. H. (2016) · Scientific Reports · doi:10.1038/srep27410 · Cited by 102
Mazurek, M., Huisman, M. V., Rothman, K. J., Paquette, M., Teutsch, C., Diener, H., Dubner, S., Halperin, J. L., Ma, C., Zint, K., et al. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-08-0555 · Cited by 105
Ischemic Stroke Risk in Patients With Nonvalvular Atrial Fibrillation
Alkhouli, M. A., & Friedman, P. A. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.10.040 · Cited by 104
Paciaroni, M., Agnelli, G., Caso, V., Silvestrelli, G., Seiffge, D. J., Engelter, S. T., Marchis, G. M. D., Polymeris, A. A., Zedde, M., Yaghi, S. R., et al. (2019) · Stroke · doi:10.1161/strokeaha.119.025350 · Cited by 102
Population-Based Screening for Atrial Fibrillation
Khurshid, S. S., Healey, J. S., McIntyre, W. F., & Lubitz, S. A. (2020) · Circulation Research · doi:10.1161/circresaha.120.316341 · Cited by 104
Sex Differences in Cardiac Arrhythmias
Ehdaie, A., Cingolani, E., Shehata, M. M., Wang, X., Curtis, A. B., & Chugh, S. S. (2018) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.117.005680 · Cited by 100
Atrial fibrillation: comorbidities, lifestyle, and patient factors
Shantsila, E., Choi, E., Lane, D. A., Joung, B., & Lip, G. Y. H. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100784 · Cited by 108
Stærk, L., Gerds, T. A., Lip, G. Y. H., Ozenne, B., Bonde, A. N., Lamberts, M., Fosbøl, E. L., Torp-Pedersen, C., Gislason, G., & Olesen, J. B. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12683 · Cited by 101
Accuracy of mHealth Devices for Atrial Fibrillation Screening: Systematic Review
Giebel, G. D., & Gissel, C. (2019) · JMIR mHealth and uHealth · doi:10.2196/13641 · Cited by 99
Cao, D., Chandiramani, R., Chiarito, M., Claessen, B. E. P. M., & Mehran, R. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa824 · Cited by 101
Chao, T., Joung, B., Takahashi, Y., Lim, T. W., Choi, E., Chan, Y., Guo, Y., Sriratanasathavorn, C., Oh, S., Okumura, K., et al. (2021) · Journal of Arrhythmia · doi:10.1002/joa3.12652 · Cited by 105
Factors XI and XII as Targets for New Anticoagulants
Weitz, J. I., & Fredenburgh, J. C. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00019 · Cited by 98
Time to Cost-Effectiveness Following Stroke Reduction Strategies in AF
Reddy, V. Y., Akehurst, R. L., Armstrong, S. O., Amorosi, S. L., Beard, S. M., & Holmes, D. R. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.09.084 · Cited by 99
Hart, R. G., Sharma, M., Mundl, H., Shoamanesh, A., Kasner, S. E., Berkowitz, S. D., Paré, G., Kirsch, B., Pogue, J., Pater, C., et al. (2016) · European Stroke Journal · doi:10.1177/2396987316663049 · Cited by 96
Evaluation of bleeding in patients receiving direct oral anticoagulants
Hellenbart, E. L., Faulkenberg, K. D., & Finks, S. W. (2017) · Vascular Health and Risk Management · doi:10.2147/vhrm.s121661 · Cited by 100
Sex Differences in Atrial Fibrillation
Andrade, J. G., Deyell, M. W., Lee, A. K. Y., & Macle, L. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.11.022 · Cited by 100
Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
Bounameaux, H., & Camm, A. J. (2014) · Drugs · doi:10.1007/s40265-014-0261-1 · Cited by 97
Alamneh, E. A., Chalmers, L., & Bereznicki, L. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0161-8 · Cited by 98
Meersch, H. V. D., Bacquer, D. D., & Vriese, A. S. D. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.09.016 · Cited by 96
Management of Spontaneous Intracerebral Hemorrhage
Veltkamp, R. C., & Purrucker, J. C. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0783-5 · Cited by 99
Cheung, C. C., Nattel, S., Macle, L., & Andrade, J. G. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.06.011 · Cited by 97
Grymonprez, M., Simoens, C., Steurbaut, S., de Backer, T. L., & Lahousse, L. (2021) · EP Europace · doi:10.1093/europace/euab303 · Cited by 102
Dagres, N., Chao, T., Fenelon, G., Aguinaga, L., Benhayon, D. A., Benjamin, E. J., Bunch, T. J., Chen, L. Y., Chen, S., Darrieux, F., et al. (2018) · EP Europace · doi:10.1093/europace/euy046 · Cited by 101
Florbetapir-PET to diagnose cerebral amyloid angiopathy
Gurol, M. E., Becker, J. A., Fotiadis, P., Riley, G. A., Schwab, K. M., Johnson, K. A., & Greenberg, S. M. (2016) · Neurology · doi:10.1212/wnl.0000000000003197 · Cited by 93
Clinician Trends in Prescribing Direct Oral Anticoagulants for US Medicare Beneficiaries
Wheelock, K. M., Ross, J. S., Murugiah, K., Lin, Z., Krumholz, H. M., & Khera, R. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.37288 · Cited by 98
Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants
Geldhof, V., Vandenbriele, C., Verhamme, P. B., & Vanassche, T. (2014) · Thrombosis Journal · doi:10.1186/1477-9560-12-21 · Cited by 96
Asirvatham, S. J., Hu, T. Y., & Vaidya, V. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s89130 · Cited by 95
Steffel, J., Verhamme, P. B., Potpara, T., Albaladejo, P., Antz, M., Desteghe, L., Hæusler, K. G., Oldgren, J., Reinecke, H., Roldán, V., et al. (2018) · Kardiologia Polska · doi:10.5603/kp.2018.0180 · Cited by 93
Secondary stroke prevention in people with atrial fibrillation: treatments and trials
Seiffge, D. J., Cancelloni, V., Räber, L., Paciaroni, M., Metzner, A., Kirchhof, P. F., Fischer, U., Werring, D. J., Shoamanesh, A., & Caso, V. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00037-1 · Cited by 101
Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Low Body Weight
Lee, S., Choi, E., Park, C. S., Han, K., Jung, J., Oh, S., & Lip, G. Y. H. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.051 · Cited by 92
Wiegele, M., Schöchl, H., Haushofer, A. C., Ortler, M., Leitgeb, J., Kwasny, O., Beer, R., Ay, C., & Schaden, E. (2019) · Critical Care · doi:10.1186/s13054-019-2352-6 · Cited by 93
Atrial fibrillation: stroke prevention
Chao, T., Potpara, T., & Lip, G. Y. H. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100797 · Cited by 103
Nielsen, P. B., Lane, D. A., Rasmussen, L. H., Lip, G. Y. H., & Larsen, T. B. (2014) · Clinical Research in Cardiology · doi:10.1007/s00392-014-0797-9 · Cited by 97
Kermer, P., Eschenfelder, C. C., Diener, H., Grond, M., Abdalla, Y., Althaus, K., Berrouschot, J., Cangür, H., Daffertshofer, M., Edelbusch, S., et al. (2017) · International Journal of Stroke · doi:10.1177/1747493017701944 · Cited by 94
Xian, Y., Xu, H., O'Brien, E. C., Shah, S. D., Thomas, L. E., Pencina, M. J., Fonarow, G. C., Olson, D. M., Schwamm, L. H., Bhatt, D. L., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2099 · Cited by 94
Alalwan, A. A., Voils, S. A., & Hartzema, A. G. (2017) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp160756 · Cited by 89
Isla, G. G., Olivares, A. L., Silva, E., Nuñez‐Garcia, M., Butakoff, C., Sánchez‐Quintana, D., Morales, H. G., Freixa, X., Noailly, J., Potter, T. J. R. D., et al. (2018) · International Journal for Numerical Methods in Biomedical Engineering · doi:10.1002/cnm.3100 · Cited by 91
Cho, M. S., Yun, J. E., Park, J. J., Kim, Y. J., Lee, J., Kim, H., Park, D., & Nam, G. (2018) · Stroke · doi:10.1161/strokeaha.118.023093 · Cited by 91
Atrial Fibrillation in Older People: Concepts and Controversies
Zathar, Z., Karunatilleke, A., Fawzy, A. M., & Lip, G. Y. H. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00175 · Cited by 94
Ingason, A. B., Hreinsson, J. P., Agustsson, A. S., Lund, S. H., Rumba, E., Pálsson, D. A., Reynisson, I. E., Guðmundsdóttir, B. R., Onundarson, P. T., & Bjornsson, E. S. (2021) · Annals of Internal Medicine · doi:10.7326/m21-1474 · Cited by 93
Testing and monitoring direct oral anticoagulants
Connors, J. M. (2018) · Blood · doi:10.1182/blood-2018-04-791541 · Cited by 92
Direct‐acting oral anticoagulants: pharmacology, indications, management, and future perspectives
Gómez‐Outes, A., Suárez‐Gea, M. L., Lecumberri, R., Terleira‐Fernández, A. I., & Vargas, E. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12610 · Cited by 96
Caluwé, R., Pyfferoen, L., Boeck, K. D., & Vriese, A. S. D. (2015) · Clinical Kidney Journal · doi:10.1093/ckj/sfv146 · Cited by 91
Angiolillo, D. J., Goodman, S. G., Bhatt, D. L., Eikelboom, J. W., Price, M. J., Moliterno, D. J., Cannon, C. P., Tanguay, J., Granger, C. B., Mauri, L., et al. (2016) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.116.004395 · Cited by 90
Direct oral anticoagulant– vs vitamin K antagonist–related nontraumatic intracerebral hemorrhage
Tsivgoulis, G. K., Lioutas, V., Varelas, P. N., Katsanos, A. H., Goyal, N., Mikulík, R., Barlinn, K., Krogias, C., Sharma, V. K., Vadikolias, Κ., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004362 · Cited by 92
Management of venous thromboembolism in pregnancy
Kalaitzopoulos, D. R., Panagopoulos, A. N., Samant, S., Ghalib, N., Kadillari, J., Daniilidis, A., Samartzis, N., Makadia, J., Palaiodimos, L., Kokkinidis, D. G., et al. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.02.002 · Cited by 94
DOACs – advances and limitations in real world
Lee, L. H. (2016) · Thrombosis Journal · doi:10.1186/s12959-016-0111-3 · Cited by 91
Effects of dabigatran according to age in atrial fibrillation
Lauw, M. N., Eikelboom, J. W., Coppens, M., Wallentin, L. C., Yusuf, S., Ezekowitz, M. D., Oldgren, J., Nakamya, J., Wang, J., & Connolly, S. J. (2017) · Heart · doi:10.1136/heartjnl-2016-310358 · Cited by 88
Takeuchi, Y., Mabe, K., Shimodate, Y., Yoshii, S., Yamada, S., Iwatate, M., Kawamura, T., Hotta, K., Nagaike, K., Ikezawa, N., et al. (2019) · Annals of Internal Medicine · doi:10.7326/m19-0026 · Cited by 88
Brambatti, M., Darius, H., Oldgren, J., Clemens, A., Noack, H., Brueckmann, M., Yusuf, S., Wallentin, L. C., Ezekowitz, M. D., Connolly, S. J., et al. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.05.141 · Cited by 90
Arihiro, S., Todo, K., Koga, M., Furui, E., Kinoshita, N., Kimura, K., Yamagami, H., Terasaki, T., Yoshimura, S., Shiokawa, Y., et al. (2016) · International Journal of Stroke · doi:10.1177/1747493016632239 · Cited by 88
2020 Clinical practice guidelines for Chronic heart failure
Russian Society of Cardiology (2020) · Russian Journal of Cardiology · doi:10.15829/29/1560-4071-2020-4083 · Cited by 88
Lip, G. Y. H., Mitchell, S., Liu, X., Liu, L. Z., Phatak, H. M., Kachroo, S., & Batson, S. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.11.084 · Cited by 90
Dagres, N., Chao, T., Fenelon, G., Aguinaga, L., Benhayon, D. A., Benjamin, E. J., Bunch, T. J., Chen, L. Y., Chen, S., Darrieux, F., et al. (2018) · Journal of Arrhythmia · doi:10.1002/joa3.12050 · Cited by 89
Initial management for acute lower gastrointestinal bleeding
Aoki, T., Hirata, Y., Yamada, A., & Koike, K. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i1.69 · Cited by 86
Oldgren, J., Steg, P. G., Hohnloser, S. H., Lip, G. Y. H., Kimura, T., Nordaby, M., Brueckmann, M., Kleine, E., ten Berg, J. M., Bhatt, D. L., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz059 · Cited by 89
Factor XI as a Target for New Anticoagulants
Fredenburgh, J. C., & Weitz, J. I. (2021) · Hämostaseologie · doi:10.1055/a-1384-3715 · Cited by 86
Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice
Roberti, R., Iannone, L. F., Palleria, C., Curcio, A., Rossi, M., Sciacqua, A., Armentaro, G., Vero, A., Manti, A., Cassano, V., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.684638 · Cited by 92
Lacunar stroke: mechanisms and therapeutic implications
Yaghi, S. R., Raz, E., Yang, D., Cutting, S., Grory, B. M., Elkind, M. S. V., & de Havenon, A. (2021) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-326308 · Cited by 94
Li, Y., Sun, K., Ye, G., Liang, Y., Pan, H., Wang, G., Zhao, Y., Pan, J., Zhang, J., & Fang, J. (2015) · Journal of Endodontics · doi:10.1016/j.joen.2014.10.020 · Cited by 91
Atrial fibrillation in women: treatment
Ko, D., Rahman, F., Martins, M. A. P., Hylek, E. M., Ellinor, P. T., Schnabel, R. B., Benjamin, E. J., & Christophersen, I. E. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.171 · Cited by 87
Clinical and Radiographic Predictors of Intracerebral Hemorrhage Outcome
Al‐Mufti, F., Thabet, A. M., Singh, T., El-Ghanem, M. H., Amuluru, K., & Gandhi, C. D. (2018) · Interventional Neurology · doi:10.1159/000484571 · Cited by 84
Efficacy of Direct Acting Oral Anticoagulants in Treatment of Left Ventricular Thrombus
Fleddermann, A. M., Hayes, C. H., Magalski, A., & Main, M. L. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.05.009 · Cited by 87
Yang, H., Bouma, B. J., Dimopoulos, K., Khairy, P., Ladouceur, M., Niwa, K., Greutmann, M., Schwerzmann, M., Egbe, A. C., Scognamiglio, G., et al. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.06.014 · Cited by 84
Grymonprez, M., Steurbaut, S., de Backer, T. L., Petrović, M., & Lahousse, L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.583311 · Cited by 84
When Direct Oral Anticoagulants Should Not Be Standard Treatment
Bejjani, A., Khairani, C. D., Assi, A. A., Piazza, G., Sadeghipour, P., Talasaz, A. H., Fanikos, J. R., Connors, J. M., Siegal, D. M., Barnes, G. D., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.10.038 · Cited by 89
Bai, Y., Guo, S.-D., Deng, H., Shantsila, A., Fauchier, L., Ma, C., & Lip, G. Y. H. (2017) · Age and Ageing · doi:10.1093/ageing/afx103 · Cited by 83
Kermer, P., Eschenfelder, C. C., Diener, H., Grond, M., Abdalla, Y., Abraham, A., Althaus, K., Becks, G., Berrouschot, J., Berthel, J., et al. (2020) · International Journal of Stroke · doi:10.1177/1747493019895654 · Cited by 84
Dalmau, G. M., Arderiu, E. S. I., Montes, M. E., Solà, I., Pequeño, S., & Alonso‐Coello, P. (2017) · BMC Family Practice · doi:10.1186/s12875-016-0574-0 · Cited by 83
Mongkhon, P., Naser, A. Y., Fanning, L., Tse, G., Lau, W. C. Y., Wong, I. C. K., & Kongkaew, C. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.10.025 · Cited by 83
Emerging anticoagulant strategies
Fredenburgh, J. C., Gross, P. L., & Weitz, J. I. (2016) · Blood · doi:10.1182/blood-2016-09-692996 · Cited by 82
Arts, D. L., Abu–Hanna, A., Medlock, S. K., & van Weert, H. C. P. M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170974 · Cited by 79
Sennesael, A., Larock, A., Douxfils, J., Elens, L., Stillemans, G., Wiesen, M. H. J., Taubert, M., Dogné, J., Spinewine, A., & Mullier, F. (2018) · Thrombosis Journal · doi:10.1186/s12959-018-0183-3 · Cited by 82
Delluc, A., Wang, T., Yap, E. S., Ay, C., Schaefer, J. K., Carrier, M., & Noble, S. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14478 · Cited by 83
Vinter, N., Huang, Q., Fenger‐Grøn, M., Frost, L., Benjamin, E. J., & Trinquart, L. (2020) · BMJ · doi:10.1136/bmj.m2724 · Cited by 81
Li, A., Li, M. K., Crowther, M. A., & Vazquez, S. R. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.08.016 · Cited by 82
Left Atrial Appendage Occlusion for Stroke Prevention in Nonvalvular Atrial Fibrillation
Collado, F. M. S., von Buchwald, C. M. L., Anderson, C. K., Madan, N., Suradi, H. S., Huang, H. D., Jneid, H. M., & Kavinsky, C. J. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.022274 · Cited by 82
Treewaree, S., Lip, G. Y. H., & Krittayaphong, R. (2023) · Thrombosis and Haemostasis · doi:10.1055/s-0043-1772773 · Cited by 87
Mobile health applications for the detection of atrial fibrillation: a systematic review
Lopez Perales, C. R., Van Spall, H. G. C., Maeda, S., Jimenez, A., Laţcu, D. G., Milman, A., Kirakoya-Samadoulougou, F., Mamas, M. A., Muser, D., & Casado Arroyo, R. (2021) · EP Europace · doi:10.1093/europace/euaa139 · Cited by 77
Lee, S., Choi, E., Han, K., Cha, M., Oh, S., & Lip, G. Y. H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189495 · Cited by 81
Sex-Based Differences in Outcomes of Oral Anticoagulation in Patients With Atrial Fibrillation
Law, S. W. Y., Lau, W. C. Y., Wong, I. C. K., Lip, G. Y. H., Mok, M. T. C., Siu, C., & Chan, E. W. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.066 · Cited by 82
Psychological aspects of atrial fibrillation: A systematic narrative review
Ladwig, K., Goette, A., Atasoy, S., & Johar, H. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01396-w · Cited by 85
Acute intracerebral haemorrhage: diagnosis and management
McGurgan, I. J., Ziai, W., Werring, D. J., Salman, R. A., & Parry‐Jones, A. (2020) · Practical Neurology · doi:10.1136/practneurol-2020-002763 · Cited by 81
Feeney, J. M., Santone, E., DiFiori, M. M., Kis, L., Jayaraman, V. M., & Montgomery, S. C. (2016) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000001245 · Cited by 81
Savarese, G., Giugliano, R. P., Rosano, G. M. C., McMurray, J. J. V., Magnani, G., Filippatos, G. S., Dellegrottaglie, S., Lund, L. H., Trimarco, B., & Filardi, P. P. (2016) · JACC Heart Failure · doi:10.1016/j.jchf.2016.07.012 · Cited by 81
Paciaroni, M., Caso, V., Agnelli, G., Mosconi, M. G., Giustozzi, M., Seiffge, D. J., Engelter, S. T., Lyrer, P. A., Polymeris, A. A., Kriemler, L. F., et al. (2022) · Stroke · doi:10.1161/strokeaha.121.038239 · Cited by 82
Managing atrial fibrillation in the very elderly patient: challenges and solutions
Letsas, Κ. P., Karamichalakis, N., Vlachos, K. G., Georgopoulos, S., Bakalakos, A., Efremidis, M., & Sideris, A. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s83664 · Cited by 86
Two-year clinical outcome from the Iberian registry patients after left atrial appendage closure
López-Mínguez, J. R., Nogales‐Asensio, J. M., Gragera, J. E., Costa, M. A. D. S., Cruz‐González, I., de Carlos, F. G., Díaz, J. A. F., Yuste, V. M., González, R. M., Domínguez-Franco, A. J., et al. (2015) · Heart · doi:10.1136/heartjnl-2014-306332 · Cited by 79
Expert opinion paper on atrial fibrillation detection after ischemic stroke
Hæusler, K. G., Gröschel, K., Köhrmann, M., Anker, S. D., Brachmann, J., Böhm, M., Diener, H., Doehner, W., Endres, M., Gerloff, C. P., et al. (2018) · Clinical Research in Cardiology · doi:10.1007/s00392-018-1256-9 · Cited by 80
Adherence to Guideline-Directed Stroke Prevention Therapy for Atrial Fibrillation Is Achievable
Piccini, J. P., Xu, H., Cox, M., Matsouaka, R., Fonarow, G. C., Butler, J., Curtis, A. B., Desai, N. R., Fang, M. C., McCabe, P. J., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.035909 · Cited by 79
Clinical Evaluation of Factor XIa Inhibitor Drugs
Harrington, J., Piccini, J. P., Alexander, J. H., Granger, C. B., & Patel, M. R. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.11.057 · Cited by 80
Werring, D. J., Dehbi, H., Ahmed, N., Arram, E., Best, J. G., Balogun, M., Bennett, K., Bordea, E., Caverly, E., Chau, M., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)02197-4 · Cited by 80
Rohla, M., Weiss, T. W., Pecen, L., Patti, G., Siller-Matula, J. M., Schnabel, R. B., SCHILLING, R. J., Kotecha, D., Lucerna, M., Huber, K., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-022478 · Cited by 84
Metadata
- Authors
- Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., Camm, A. J., Weitz, J. I., Lewis, B. S., Parkhomenko, A., Yamashita, T., & Antman, E. M.
- Affiliations
- Brigham and Women's Hospital (US)
- Thomas Jefferson University (US)
- St George's, University of London (GB)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Carmel Medical Center (IL)
- Cardiovascular Institute Hospital (JP)
- Corresponding author
- Ruff, Christian T
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 383
- Issue
- 9921
- Pages
- 955-962
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2152623033
- Cited by
- 5,051
- References
- 45
- Citations by year
- 2026: 249 · 2025: 310 · 2024: 399 · 2023: 426 · 2022: 410 · 2021: 490 · 2020: 521 · 2019: 462 · 2018: 456 · 2017: 447 · 2016: 406 · 2015: 318 · 2014: 139
- FWCI
- 49.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- direct oral anticoagulants, warfarin, atrial fibrillation, stroke prevention, systemic embolism, hemorrhagic stroke, intracranial hemorrhage, gastrointestinal bleeding, major bleeding, all-cause mortality, subgroup analysis, factor Xa inhibitors, dabigatran, rivaroxaban, apixaban
- MeSH terms
- Administration, Oral, Anticoagulants, Atrial Fibrillation, Embolism, Humans, Warfarin, Randomized Controlled Trials as Topic, Treatment Outcome, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
